Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, Baum SJ, Hurh E, Bartlett VJ, Kingsbury J, Figueroa AL, Alexander VJ, Tami J, Witztum JL, Geary RS, O'Dea LSL, Tsimikas S, Gaudet D. Tardif JC, et al. Among authors: hurh e. Eur Heart J. 2022 Apr 6;43(14):1401-1412. doi: 10.1093/eurheartj/ehab820. Eur Heart J. 2022. PMID: 35025993 Free PMC article. Clinical Trial.
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S. Graham MJ, et al. Among authors: hurh e. N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24. N Engl J Med. 2017. PMID: 28538111 Free article. Clinical Trial.
Treatment with Volanesorsen, a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers.
Watts LM, Karwatowska-Prokopczuk E, Hurh E, Alexander VJ, Balogh K, O'Dea L, Geary RS, Tsimikas S. Watts LM, et al. Among authors: hurh e. Nucleic Acid Ther. 2020 Aug;30(4):198-206. doi: 10.1089/nat.2019.0837. Epub 2020 Jun 23. Nucleic Acid Ther. 2020. PMID: 32589506 Free PMC article. Clinical Trial.
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, Figueroa AL, Piscitelli P, Singleton W, Witztum JL, Geary RS, Tsimikas S, O'Dea LSL; Vupanorsen Study Investigators. Gaudet D, et al. Among authors: hurh e. Eur Heart J. 2020 Oct 21;41(40):3936-3945. doi: 10.1093/eurheartj/ehaa689. Eur Heart J. 2020. PMID: 32860031 Free PMC article. Clinical Trial.
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, Hughes SG, Gaudet D, Hegele RA, O'Dea LSL, Stroes ESG, Tsimikas S, Witztum JL; COMPASS study group. Gouni-Berthold I, et al. Among authors: hurh e. Lancet Diabetes Endocrinol. 2021 May;9(5):264-275. doi: 10.1016/S2213-8587(21)00046-2. Epub 2021 Mar 30. Lancet Diabetes Endocrinol. 2021. PMID: 33798466 Clinical Trial.
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
Foss-Freitas MC, Akinci B, Neidert A, Bartlett VJ, Hurh E, Karwatowska-Prokopczuk E, Oral EA. Foss-Freitas MC, et al. Among authors: hurh e. Lipids Health Dis. 2021 Dec 5;20(1):174. doi: 10.1186/s12944-021-01589-4. Lipids Health Dis. 2021. PMID: 34865644 Free PMC article. Clinical Trial.
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
Oral EA, Garg A, Tami J, Huang EA, O'Dea LSL, Schmidt H, Tiulpakov A, Mertens A, Alexander VJ, Watts L, Hurh E, Witztum JL, Geary RS, Tsimikas S. Oral EA, et al. Among authors: hurh e. J Clin Lipidol. 2022 Nov-Dec;16(6):833-849. doi: 10.1016/j.jacl.2022.08.008. Epub 2022 Sep 22. J Clin Lipidol. 2022. PMID: 36402670 Clinical Trial.
Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects.
Karwatowska-Prokopczuk E, Lesogor A, Yan JH, Hurh E, Hoenlinger A, Margolskee A, Xia S, Tsimikas S. Karwatowska-Prokopczuk E, et al. Among authors: hurh e. J Clin Lipidol. 2023 Jan-Feb;17(1):181-188. doi: 10.1016/j.jacl.2022.12.001. Epub 2022 Dec 8. J Clin Lipidol. 2023. PMID: 36529659 Clinical Trial.
33 results